Straits Times Index
3,262.54 +7.00 (+0.22%) S&P 500
4,011.54 +40.27 (+1.01%) Dow
32,612.95 +218.70 (+0.68%) Nasdaq
11,872.55 +156.47 (+1.34%) Bitcoin USD
28,438.94 +1,471.53 (+5.46%) CMC Crypto 200
620.18 +19.21 (+3.20%)
ABBV Jan 2025 135.000 put
| Previous close | 9.65 |
| Open | 9.67 |
| Bid | 9.50 |
| Ask | 9.80 |
| Strike | 135.00 |
| Expiry date | 2025-01-17 |
| Day's range | 9.65 - 9.67 |
| Contract range | N/A |
| Volume | |
| Open interest | 54 |
- Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
- Motley Fool
2 Relatively Safe Dividend Stocks You Won't Regret Owning
While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effective competition and their management's skill at executing their business models. Both of the stocks I'll review in a moment are likely to keep growing and paying their shareholders for a very long time, and that means you aren't likely to regret making a purchase. When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list.
- Motley Fool
This Is the Best Dividend ETF You Can Buy
The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position.
